Youssef S, Osman L, Sabbour M S
Department of Medicine and Clinical Pathology, Ain-Shams University Cairo, Egypt.
Int J Clin Pharmacol Res. 1992;12(3):109-16.
Serum lipids of 80 patients with moderately severe essential hypertension under four different antihypertensive therapies were compared to ten matched hypertensives on a placebo, after eight weeks of therapy. The results in the serum lipid parameters measured after therapy showed with enalapril a significant increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in the total cholesterol/HDL-C ratio. With benazepril a significant decrease in the total cholesterol/HDL-C ratio was obtained. With the diuretic combination Epitens the effect on serum sodium and potassium was minimal. No significant changes were found in the lipoprotein profile following the administration of the placebo. Both angiotensin converting enzyme inhibitors (enalapril and benazapril) induced a significant improvement in the atherogenic ratio; as well as the calcium antagonist (isradipine), though to a less extent. The diuretic Epitens induced an insignificant deterioration of the atherogenic ratio.
在治疗八周后，对80例中度严重原发性高血压患者采用四种不同抗高血压疗法治疗后的血脂情况，与10例匹配的服用安慰剂的高血压患者进行了比较。治疗后测量的血清脂质参数结果显示，依那普利使高密度脂蛋白胆固醇（HDL-C）显著升高，总胆固醇/HDL-C比值降低。使用贝那普利可使总胆固醇/HDL-C比值显著降低。使用利尿剂组合Epitens对血清钠和钾的影响最小。服用安慰剂后脂蛋白谱未发现显著变化。两种血管紧张素转换酶抑制剂（依那普利和贝那普利）均使致动脉粥样硬化比值显著改善；钙拮抗剂（伊拉地平）也是如此，不过程度较小。利尿剂Epitens使致动脉粥样硬化比值出现不显著的恶化。
